Evidence map›Paper›PMID 32504035›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Molecular characterization of diffuse malignant peritoneal mesothelioma.

Yin P Hung, Fei Dong, Matthew Torre, Christopher P Crum, Raphael Bueno, Lucian R Chirieac

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Malignant Peritoneal Mesothelioma.Chonnam medical journal · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yin P HungDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. yphung@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-8568-1591
Fei DongDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Matthew TorreDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Christopher P CrumDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Raphael BuenoDepartment of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Lucian R ChirieacDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. lchirieac@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-4383-6938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant peritoneal mesothelioma is a rare aggressive tumor that arises from the peritoneal lining. While recurrent BAP1 mutations have been identified in a subset of mesotheliomas, molecular characteristics of peritoneal mesotheliomas, including those lacking BAP1 alterations, remain poorly understood. Using targeted next-generation sequencing, we examined the molecular features of 26 diffuse malignant peritoneal mesotheliomas. As part of an exploratory analysis, we analyzed an additional localized peritoneal mesothelioma and one well-differentiated papillary mesothelioma with invasive foci. Genomic characterization identified categories of diffuse malignant peritoneal mesotheliomas: The first group included 18 (69%) tumors with recurrent BAP1 alterations, with eight (31%) having more than one BAP1 alterations, and concomitant alterations in PBRM1 (46%) and SETD2 (35%). All tumors with complete loss of BAP1 expression by immunohistochemistry harbored BAP1 molecular alterations. PBRM1 alterations were significantly enriched in the BAP1-altered cohort. Frequent copy number loss of BAP1, ARID1B, PRDM1, PBRM1, SETD2, NF2, and CDKN2A was noted. The second group included eight (31%) BAP1-wild-type tumors: two with TP53 mutations, one with a TRAF7 activating mutation, one with a SUZ12 inactivating mutation, and three with ALK rearrangements that we previously published. One TP53-mutant biphasic mesothelioma showed evidence of genomic near-haploidization showing loss of heterozygosity of all chromosomes except 5, 7, 16, and 20. The localized peritoneal mesothelioma harbored a nonsense CHEK2 mutation, and the well-differentiated papillary mesothelioma with invasive foci harbored no reportable variants. In conclusion, we described the genetic categories of diffuse malignant peritoneal mesotheliomas, with BAP1-mutant and BAP1-wild-type groups. Our findings implicated DNA repair, epigenetics, and cell cycle regulation in the pathogenesis of peritoneal mesotheliomas, with identification of potential therapeutic targets.

Indexed as

AdultAgedBiomarkers, TumorDNA-Binding ProteinsFemaleHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansMaleMesothelioma, MalignantMiddle AgedPeritoneal NeoplasmsPeritoneumTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanBiomarkers, TumorDNA-Binding ProteinsHistone-Lysine N-MethyltransferasePBRM1 protein, humanSETD2 protein, humanTranscription FactorsTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID32504035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.